Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy

RK. Bogan, MJ. Thorpy, Y. Dauvilliers, M. Partinen, R. Del Rio Villegas, N. Foldvary-Schaefer, R. Skowronski, L. Tang, F. Skobieranda, K. Šonka

. 2021 ; 44 (3) : . [pub] 20210312

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019055
E-zdroje Online Plný text

NLK Free Medical Journals od 1978 do Před 6 měsíci
ProQuest Central od 2016-10-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2016-10-01 do Před 1 rokem
Psychology Database (ProQuest) od 2016-10-01 do Před 1 rokem

Odkazy

PubMed 33184650
DOI 10.1093/sleep/zsaa206
Knihovny.cz E-zdroje

STUDY OBJECTIVES: Evaluate efficacy and safety of lower-sodium oxybate (LXB), a novel oxybate medication with 92% less sodium than sodium oxybate (SXB). METHODS: Adults aged 18-70 years with narcolepsy with cataplexy were eligible. The study included a ≤30-day screening period; a 12-week, open-label, optimized treatment and titration period to transition to LXB from previous medications for the treatment of cataplexy; a 2-week stable-dose period (SDP); a 2-week, double-blind, randomized withdrawal period (DBRWP); and a 2-week safety follow-up. During DBRWP, participants were randomized 1:1 to placebo or to continue LXB treatment. RESULTS: Efficacy was assessed in 134 participants who received randomized treatment, and safety was assessed in all enrolled participants (N = 201). Statistically significant worsening of symptoms was observed in participants randomized to placebo, with median (first quartile [Q1], third quartile [Q3]) change in weekly number of cataplexy attacks from SDP to DBRWP (primary efficacy endpoint) in the placebo group of 2.35 (0.00, 11.61) versus 0.00 (-0.49, 1.75) in the LXB group (p < 0.0001; mean [standard deviation, SD] change: 11.46 [24.751] vs 0.12 [5.772]), and median (Q1, Q3) change in Epworth Sleepiness Scale score (key secondary efficacy endpoint) of 2.0 (0.0, 5.0) in the placebo group versus 0.0 (-1.0, 1.0) in the LXB group (p < 0.0001; mean [SD] change: 3.0 [4.68] vs 0.0 [2.90]). The most common treatment-emergent adverse events with LXB were headache (20.4%), nausea (12.9%), and dizziness (10.4%). CONCLUSIONS: Efficacy of LXB for the treatment of cataplexy and excessive daytime sleepiness was demonstrated. The safety profile of LXB was consistent with SXB. CLINICAL TRIAL REGISTRATION: NCT03030599.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019055
003      
CZ-PrNML
005      
20210830100628.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/sleep/zsaa206 $2 doi
035    __
$a (PubMed)33184650
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bogan, Richard K $u School of Medicine, University of South Carolina, Columbia, SC
245    10
$a Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy / $c RK. Bogan, MJ. Thorpy, Y. Dauvilliers, M. Partinen, R. Del Rio Villegas, N. Foldvary-Schaefer, R. Skowronski, L. Tang, F. Skobieranda, K. Šonka
520    9_
$a STUDY OBJECTIVES: Evaluate efficacy and safety of lower-sodium oxybate (LXB), a novel oxybate medication with 92% less sodium than sodium oxybate (SXB). METHODS: Adults aged 18-70 years with narcolepsy with cataplexy were eligible. The study included a ≤30-day screening period; a 12-week, open-label, optimized treatment and titration period to transition to LXB from previous medications for the treatment of cataplexy; a 2-week stable-dose period (SDP); a 2-week, double-blind, randomized withdrawal period (DBRWP); and a 2-week safety follow-up. During DBRWP, participants were randomized 1:1 to placebo or to continue LXB treatment. RESULTS: Efficacy was assessed in 134 participants who received randomized treatment, and safety was assessed in all enrolled participants (N = 201). Statistically significant worsening of symptoms was observed in participants randomized to placebo, with median (first quartile [Q1], third quartile [Q3]) change in weekly number of cataplexy attacks from SDP to DBRWP (primary efficacy endpoint) in the placebo group of 2.35 (0.00, 11.61) versus 0.00 (-0.49, 1.75) in the LXB group (p < 0.0001; mean [standard deviation, SD] change: 11.46 [24.751] vs 0.12 [5.772]), and median (Q1, Q3) change in Epworth Sleepiness Scale score (key secondary efficacy endpoint) of 2.0 (0.0, 5.0) in the placebo group versus 0.0 (-1.0, 1.0) in the LXB group (p < 0.0001; mean [SD] change: 3.0 [4.68] vs 0.0 [2.90]). The most common treatment-emergent adverse events with LXB were headache (20.4%), nausea (12.9%), and dizziness (10.4%). CONCLUSIONS: Efficacy of LXB for the treatment of cataplexy and excessive daytime sleepiness was demonstrated. The safety profile of LXB was consistent with SXB. CLINICAL TRIAL REGISTRATION: NCT03030599.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a vápník $7 D002118
650    12
$a kataplexie $x farmakoterapie $7 D002385
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé $7 D006801
650    _2
$a hořčík $7 D008274
650    _2
$a lidé středního věku $7 D008875
650    12
$a narkolepsie $x farmakoterapie $7 D009290
650    _2
$a draslík $7 D011188
650    _2
$a sodík $7 D012964
650    12
$a oxybát sodný $x škodlivé účinky $x terapeutické užití $7 D012978
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Thorpy, Michael J $u Department of Neurology, Albert Einstein College of Medicine, Bronx, NY
700    1_
$a Dauvilliers, Yves $u Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France $u Department of Neurology, University of Montpellier, INSERM U1061, Montpellier, France
700    1_
$a Partinen, Markku $u Helsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland
700    1_
$a Del Rio Villegas, Rafael $u Neurophysiology and Sleep Disorders Unit, Hospital Vithas Nuestra Señora de America, Madrid, Spain
700    1_
$a Foldvary-Schaefer, Nancy $u Sleep Disorders Center, Cleveland Clinic, Cleveland, OH
700    1_
$a Skowronski, Roman $u Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA
700    1_
$a Tang, Lihua $u Biostatistics, Jazz Pharmaceuticals, Inc., Palo Alto, CA
700    1_
$a Skobieranda, Franck $u Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA
700    1_
$a Šonka, Karel $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
773    0_
$w MED00004377 $t Sleep $x 1550-9109 $g Roč. 44, č. 3 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33184650 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100629 $b ABA008
999    __
$a ok $b bmc $g 1689980 $s 1139501
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 44 $c 3 $e 20210312 $i 1550-9109 $m Sleep $n Sleep $x MED00004377
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace